Murat Kürtüncü
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Murat Kürtüncü has a total of 213 co-authors. Here are the top co-authors by number of shared publications:
- Tuncay Gündüz
Department of Neurology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey
18 shared publications - Erdem Tüzün
Istanbul University
9 shared publications Tuncay Gündüz
9 shared publicationsAhmed Serkan Emekli
Department of Neurology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Türkiye
7 shared publications- Mefkure Eraksoy
Department of Neurology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey
6 shared publications - Gizem Yağmur Yalçın
Department of Nursing, Faculty of Health Sciences, Istinye University, Istanbul, Türkiye
5 shared publications
Latest Publications
- 21 October 2026
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 116
Clinical and radiological features of anti-MOG-associated cerebral cortical encephalitis
- 21 October 2026
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 116
Clinical and radiological features of anti-MOG-associated cerebral cortical encephalitis
- 20 October 2026
- Published by Taylor & Francis in Journal of Sex & Marital Therapy
- p. 1-13
The Effect of Sexual Counseling with the PLISSIT Model on Sexual Function and Sexual Quality of Life in Women with Multiple Sclerosis: A Randomized Controlled Trial
Sexual dysfunction is prevalent among women with multiple sclerosis (MS) and significantly impairs their sexual quality of life (Dehghaniathar et al., 2025; Salari et al., 2023; Yeni et al., 2025)....
- 20 October 2026
- Published by Taylor & Francis in Journal of Sex & Marital Therapy
- p. 1-13
The Effect of Sexual Counseling with the PLISSIT Model on Sexual Function and Sexual Quality of Life in Women with Multiple Sclerosis: A Randomized Controlled Trial
Sexual dysfunction is prevalent among women with multiple sclerosis (MS) and significantly impairs their sexual quality of life (Dehghaniathar et al., 2025; Salari et al., 2023; Yeni et al., 2025)....
- Open Access
- 6 July 2026
- Published by AVES YAYINCILIK A.Ş. in Turkish Journal of Nephrology
- Vol. 35 (3) , 256-257
Progressive Multifocal Leukoencephalopathy in a Kidney Transplant Recipient
Cite this article as: Tahillioglu Y, Mirioglu S, Ucar AR, et al. Progressive multifocal leukoencephalopathy in a kidney transplant recipient. Turk J Nephrol. 2026;35(3):256-257.
- 6 July 2026
- Published by AVES YAYINCILIK A.Ş. in Turkish Journal of Nephrology
- Vol. 35 (3) , 256-257
Open AccessProgressive Multifocal Leukoencephalopathy in a Kidney Transplant Recipient
Cite this article as: Tahillioglu Y, Mirioglu S, Ucar AR, et al. Progressive multifocal leukoencephalopathy in a kidney transplant recipient. Turk J Nephrol. 2026;35(3):256-257.
- 6 June 2026
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 112, 107304
Association of somatosensory evoked potentials with cervical spinal cord atrophy and disability progression in multiple sclerosis
- 6 June 2026
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 112, 107304
Association of somatosensory evoked potentials with cervical spinal cord atrophy and disability progression in multiple sclerosis
- 23 March 2026
- Published by Springer Nature in Acta Neurologica Belgica
- Vol. 126 (4) , 1-9
Comorbid autoimmune diseases do not influence long-term disability progression in multiple sclerosis
- 23 March 2026
- Published by Springer Nature in Acta Neurologica Belgica
- Vol. 126 (4) , 1-9
Comorbid autoimmune diseases do not influence long-term disability progression in multiple sclerosis
- Open Access
- 8 January 2026
- Published by Springer Nature in Journal of Neurology
- Vol. 273 (1) , 67
Real-world effectiveness and safety of eculizumab in AQP4-IgG-positive neuromyelitis optica spectrum disorder
Objective: To evaluate the real-world effectiveness and safety of eculizumab in patients with AQP4-IgG–positive neuromyelitis optica spectrum disorder (NMOSD) and to identify predictors of disability outcomes. Methods: This multinational, retrospective cohort study analyzed data from 46 patients across 26 centers. The outcomes included the annualized relapse rate (ARR), relapse-free status, change in expanded disability status scale (EDSS) scores, and adverse events. To identify predictors of EDSS improvement or worsening, patients were stratified into subgroups (improved vs. stable/worsened) at each follow-up time point and compared based on demographic, clinical, and radiological variables. Results: This retrospective cohort study included 46 patients with AQP4-IgG-positive NMOSD from 26 centers, followed for a mean of 27.3 months. The mean ARR significantly decreased from 1.1 in the 2 years pre-treatment to 0.1 during eculizumab therapy. The relapse-free rate increased from 6.5% pre-treatment to 80.4%. Mean EDSS scores improved from 4.2 at baseline to 3.6 at 24 months. The presence of area postrema syndrome was associated with a favorable prognosis, while the presence of spinal attacks was associated with a poor prognosis at 12 months. Adverse events occurred in 7 patients (18.9%), leading to permanent discontinuation in only two. Conclusion: Eculizumab demonstrated robust real-world effectiveness in reducing relapse rates and stabilizing disability, with an acceptable safety profile. Clinical outcomes may be influenced by attack phenotype, underscoring the importance of early intervention.
- 8 January 2026
- Published by Springer Nature in Journal of Neurology
- Vol. 273 (1) , 67
Open AccessReal-world effectiveness and safety of eculizumab in AQP4-IgG-positive neuromyelitis optica spectrum disorder
Objective: To evaluate the real-world effectiveness and safety of eculizumab in patients with AQP4-IgG–positive neuromyelitis optica spectrum disorder (NMOSD) and to identify predictors of disability outcomes. Methods: This multinational, retrospective cohort study analyzed data from 46 patients across 26 centers. The outcomes included the annualized relapse rate (ARR), relapse-free status, change in expanded disability status scale (EDSS) scores, and adverse events. To identify predictors of EDSS improvement or worsening, patients were stratified into subgroups (improved vs. stable/worsened) at each follow-up time point and compared based on demographic, clinical, and radiological variables. Results: This retrospective cohort study included 46 patients with AQP4-IgG-positive NMOSD from 26 centers, followed for a mean of 27.3 months. The mean ARR significantly decreased from 1.1 in the 2 years pre-treatment to 0.1 during eculizumab therapy. The relapse-free rate increased from 6.5% pre-treatment to 80.4%. Mean EDSS scores improved from 4.2 at baseline to 3.6 at 24 months. The presence of area postrema syndrome was associated with a favorable prognosis, while the presence of spinal attacks was associated with a poor prognosis at 12 months. Adverse events occurred in 7 patients (18.9%), leading to permanent discontinuation in only two. Conclusion: Eculizumab demonstrated robust real-world effectiveness in reducing relapse rates and stabilizing disability, with an acceptable safety profile. Clinical outcomes may be influenced by attack phenotype, underscoring the importance of early intervention.
- 5 January 2026
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 107, 106964
Early determinants of long-term outcomes in multiple sclerosis
- 5 January 2026
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 107, 106964
Early determinants of long-term outcomes in multiple sclerosis